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IgM rheumatoid factors (RF) have the potential to cause 
false-positive reactions in the indirect immunofluorescence 
(IIF) and enzyme immunoassay (EIA) tests for rubella IgM anti-
body. Sixty laboratories were selected from the Centers for 
Disease Control (CDC) Proficiency Testing Program to partici-
pate in a special study which evaluated this potential. 
Eight of ten serum pools were prepared by combining pre-
assayed rubella IgG antibody positive sera with lgM RF positive 
sera. The activity of the pools were adjusted to desired con-
centrations by adding serum with a high or low rubella lgG anti-
body titer, serum positive for IgM RF, or serum nonreactive for 
both rubella antibody and lgM RF. The pools were determined to 
have no detectable rubella IgM antibody using hemagglutination-
i i i 
inhibition (HAl) in conjunction with ion exchange chromato-
graphy. Of the other two pools, one was negative for both 
rubella antibodies and RF, and the other was prepared from 
serum taken from a susceptible donor four weeks after vacci-
nation with rubella vaccine and was positive in the lgM frac-
tion for rubella antibody. 
Thirty of the 60 laboratories were selected to quantitate 
rubella (IgM and/or lgG) antibody using IIF, EIA, or HAl. 
The remaining 30 laboratories were selected to quantitate RF. 
False-positive reactions in IIF tests for rubella IgM antibody 
were found to occur in two basic conditions: 1. high 
concentrations of IgM RF with relatively low concentrations 
of rubella IgG antibody; and 2. · hi.gh concentrations of 
rubella lgG antibody with relatively low concentrations of 
IgM RF. A more detailed study would be required to determine 
the optimal relative concentrations of rubella IgG antibody 
and IgM RF required to cause false-positive reactions in the 
rubella IIF test. There were no false-positive rubella lgM 
antibody results reported using the EIA test. However, addi-
tional investigation including a larger number of laboratories 
would be necessary to determine if IgM RF can cause false-posi-
tive reactions in the EIA test for rubella IgM antibody. 
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Rubella antibodies are, to an increasing degree, detec-
ted by immunoassays that use labeled anti-human immunoglobu-
lins. Indirect immunofluorescence (IIF), enzyme immunoassay 
(EIA), and radioimmunoassays (RIA) are techniques being inves-
tigated or presently applied in rubella serology. A great 
advantage of these assays is the capability for a rapid diag-
nosis of a recent primary infection by demonstrating specific 
IgM class antibodies (those antibodies which are generated 
early after an infection occurs and which precede the later 
and more prevalent IgG antibodies). However, in assays which 
detect rubella lgM antibodies with anti-human lgM immunoglo-
bulins, IgM rheumatoid factors (RF) have been shown to be 
capable of causing (by intrusive binding) false-positive 
rubella IgM reactions with RIA (Meurman and Ziola, 1978). 
IgM RF intrusion occurs when rubella lgG antibodies bind to 
the test system antigen and provide binding sites on the Fe 
portion of the IgG molecule for any available lgM RF. The 
test antigen-rubella IgG antibodies - lgM RF complexes are 
subsequently revealed by the conjugated anti-human IgM anti-
bodies producing a false-positive reaction for rubella IgM 
antibody. 
Although the widespread use of rubella vaccination has 
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c u rt a i 1 e d the i n c i den c e of rube 1 1 a i n f e c t i on , s p or ad i c cases 
and minor epidemics do still occur. Thus, the chance of 
infection occurring during a woman's first trimester of 
pregnancy, with resultant congenital defects in the fetus 
does exist (Christenson, 1980). In the unfortunate cases in 
which rubella is serologically confirmed, the patients often 
elect abortion. Ideally, the susceptibility of women of 
childbearing age to rubella infection should be determined 
before pregnancy; those found susceptible should be vaccinated 
and tested to ensure seroconversion occurred. In fact, some 
states require rubella testing before obtaining marriage 
licenses. However, when no previous serologic tests for 
rubella virus have been performed and the pregnant patient 
has been exposed to rubella, it becomes necessary to perform 
a rapid and accurate serologic diagnosis. 
The most effective laboratory method for diagnosing early 
rubella infection has been to simultaneously test acute-and 
convalescent-phase sera in the traditional hemagglutination-
inhibition (HAl) test. A significant rise in antibody titer 
is usually indicative of a recent infection. In such cases, 
the patient may have either a recent primary infection which 
puts the fetus at risk or a reinfection with a secondary 
antibody response which poses no threat to the fetus. When 
pregnancy is involved, it is important to distinguish between 
the two possibilities by testing the serum for rubella IgM 
antibody. At present, the rubella lgM antibody test utilizes 
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protein separation techniques to fractionate the serum into 
IgG and IgM isolates or absorption of IgG by protein A. The 
IgM fractions are then assayed for rubella antibodies by using 
the HAl test. This procedure is tedious and time consuming, 
and depending on the separation technique employed, it could 
also be rather expensive. 
The diagnosis of a recent primary rubella infection 
during early pregnancy is of the utmost importance because of 
the effects of the organism on the fetus. Therefore, sero-
logical tests designed to detect IgM specific antibody to 
rubella are a valuable aid in predicting the possible outcome 
of a pregnancy. However, if IgM RF interferes and alters the 
test results in such a way to indicate infection, it could 
result in the termination of a pregnancy in which the fetus 
has not been threatened by the organism. For this reason, 
the potential of IgM RF to cause false-positive reactions for 
rubella IgM antibody in the IIF and EIA tests was evaluated. 
Both methods utilize anti-human IgM immunoglobulins, which 
cannot distinguish between rubella IgM antibody and IgM RF, 
to detect IgM specific antibody to rubella. 
--- --- -------
CHAPTER II 
REVIEW OF LITERATURE 
Rubella and Congenital Defects 
Reports from Australia in the early 1940s suggested 
that congenital malformations occurred in seriously high 
frequency among infants whose mothers had had rubella in 
the early part of their pregnancy. In the first half of the 
year 1941, an unusual number of congenital cataracts made 
their appearance in Sydney, Australia (Gregg, 1942, 1945). 
Enquiries into the medical history of the mothers during the 
early months of pregnancy revealed that all but 10 gave a 
history of rubella, usually during the first or second month 
of pregnancy. Shortly after, a committee was appointed by 
the Director General of Health to investigate cases of similar 
type which appeared during the same period in other areas of 
Australia. The committee reported that of 180 congenital 
defective children, a history of maternal rubella had been 
revealed in 130 cases. These investigations confirmed and 
amplified the original findings of Gregg. 
In southern Australia in 1942, Swann and his co-workers 
(1943, 1944, 1946) began their extensive work in the field. 
They published a series of papers giving the results of their 
investigations. Altogether, 120 defective children were inve-
stigated and in 101 cases rubella had occurred during pregnancy. 
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In the majority of cases, rubella had occurred within the 
, first four months of pregnancy and there was some evidence 
that the type of defect was related to the time when rubella 
occurred. Heart and eye defects were most common when rubella 
occurred in the first and second months, and hearing defects 
when rubella had been in the second and third months. In the 
1943 paper it was stated: 
On the available evidence, when a woman contracts 
rubella within the first two months of pregnancy 
it would appear that the chances of her giving 
birth to a congenitally defective child are in 
the region of 100 per cent. If she contracts 
rubella in the third month they are about 50 
per cent. There is also a slight likelihood 
that the child will be congenitally defective 
if rubella is contracted after the third month 
of pregnancy. 
Following the publication of the Australian accounts of 
an association between maternal rubella during pregnancy and 
subsequent congenital defects in the child, confirmatory 
papers appeared in the United States (Reese, 1944; Erickson, 
1944), but it was not until 1947 that the observation made a 
major impact on medical thought. Conrad Wesselhoeft (1947) 
published a comprehensive paper on rubella in the New England 
Journal of Medicine drawing world attention to the veracity 
a n d i m p o rt a n c e of Greg g • s o b s e r vat i on s • In this paper, he 
discusses many aspects of the disease and records a summary 
of 30 papers, relating rubella to 521 instances of fetal 
deformity. 
In England, Clayton-Jones and Camb (1947) made a study 
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of deaf children by means of questionnaires which were sent 
to the mothers of children in deaf school. Out of 141 cases 
19 mothers gave a history of rubella during pregnancy, which 
in all cases had been within the first four months. Bradford 
Hill and Galloway (1958) used National Health Insurance 
records of employed women to pinpoint cases of virus infection 
followed by maternity during a twelve month period. Forty-
four cases of rubella were found and the children were subse-
quently examined. Of 18 first trimester infections, there 
were 13 normal children, 4 had characteristic malformations, 
and one died unexamined. The authors concluded that their 
mode of enquiry threw no new light on the possibility of virus 
infection causing fetal abnormalities. 
Lundstrom (1962) recorded the effects of a 1951 rubella 
epidemic in Sweden on the pregnancies of women who contracted 
or were in contact with rubella. From a series of 1,067 
rubella cases, it was found that when rubella occurred during 
the first four months of pregnancy the incidence of abnormality 
which included still births, neonatal deaths, abnormalities and 
prematurity was 17 per cent. A high incidence of abnormality 
was also found among women who had earlier suffered from 
rube 11 a and had been exposed to i n f e c t i on d u r i n g the f i r s t 
four months of the current pregnancy but had not contracted the 
disease. Lundstrom concluded that defects occurred most 
frequently when rubella occurred early in gestation. 
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Although the incidence of malformations due to congenital 
rubella varied from one study to another, most investigators 
agreed that rubella infection during the first trimester of 
pregnancy can cause fetal damage. Though deafness, cataracts, 
and congenital heart disease were for many years considered 
the congenital rubella syndrome, this triad had now been 
expanded to include defects ranging from the most obvious and 
severe to the most subtle, with hardly a body organ left 





11 new rube 1 1 a 
rubella are now subsumed under 
syndrome .. (Lindquist, et al., 
Rubella Virus 
The observations of Gregg (1942), linking the occurrence 
of rubella in early pregnancy and the congenital defects 
resulting in the newborn, stimulated interest in the disease 
and in measures which might lead to its control. It was not 
until 1962, however, that recovery of the virus was accom-
plished by Weller and Neva (1962) at the Harvard School of 
Public Health and by Parkman et al. (1962) at the Walter 
Reed Army Institute of Research. Each group worked indepen-
dently and used different techniques. At Harvard, the pre-
sence of rubella virus was recognized in human amnion cell 
cultures by the appearance of a subtle cytopathic effect 
(CPE). Affected cells scattered throughout the cell sheet 
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became refractile, irregularly elongated or ameboid in shape, 
and detached from the glass. At Walter Reed, it was found 
that rubella virus infected African green monkey kidney (GMK) 
cells were resistant to the CPE induced by echo-virus type 
II. These findings were rapidly confirmed by other investi-
gators (Veronelli et al., 1962; Green et al., 1965). 
Morphologically, electron microscopic studies by several 
groups showed that the rubella virion is approximately 60 
millimicrons in diameter (Best et al., 1967; Holmes and War-
burton, 1967; Almeida and Laurance, 1969; Russell et al., 
1967). The virus particles observed were spherical or oval 
and varied in size within the range of 40 to an millimicrons. 
These studies agreed with earlier size estimates based on fil-
tration characteristics, which indicated that the virus readily 
passed permeable membranes of 220 to 260 millimicron average 
pore diameter but was retained by those of 50 to 71 millimi-
cron size (Weller and Neva, 1962; Parkman et al., 1962). The 
virion consists of a roughly isometric internal nucleocapsid 
covered by a loose envelope. Negative staining technics 
revealed small spikes projecting from the envelope of most 
pa rt i c 1 es. 
The lack of inhibition of virus growth in cultures main-
t a i n e d w i t h me d i u m co n t a i n i n g 5- I o do- 2 • 0 eo xy u r i d i n e ( P a r k man 
et al., 1964; Cusumano et al., 1964) and 5-Fluorodeoxyuridine 
(Maassab and Cochran, 1964) provided evidence that the virus 
genetic material is of the ribonucleic acid (RNA) type. The 
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virion contains one molecule of single-stranded RNA of 38-40s 
and has a molecular weight of 2.5-3.0 x 106 daltons. Infec-
tivity was readily destroyed by treatment with ether, chloro-
form, trypsin, and formaldehyde solution (Weller and Neva, 
1962; Parkman et al., 1962}. The loss of infectivity with 
those agents indicates the presence of an essential lipid. 
In addition, the virus was destroyed rapidly at 56 C and its 
stability was affected adversely at pH levels below 6.8 and 
above 8.1 (Chagnon and Laflamme, 1964}. At pH 3.0, the 
infectivity was de~troyed completely. Although the virus is 
relatively labile, it can be kept viable for several years by 
storing at -70 C. 
On the bases of the aforementioned physical and chemical 
characteristics, rubella virus is classified as a toga virus 
(genus Rubivirus} (Davis, 1980}. As with other toga viruses, 
the infectious virion RNA initiates viral replication by 
serving as a mRNA for viral protein synthesis. Viral multi-
plication is confined to the cytoplasm, and its RNA synthesis 
proceeds through intermediate forms. Morphogenesis of the 
virions occurs at cell membranes (particular the plasma mem-
brane}, which differentiate by incorporating viral proteins. 
Nucleocapsids then bud through the thickened vacuolar and 
surface membranes to form mature viral particles. 
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Serologic Procedures !~!!9.nosing Primary Rubella Infections 
A variety of serologic test methods have been utilized 
to diagnose primary rubella infections by detecting specific 
IgM class antibody. Demonstration of a decrease in antibody 
titer following treatment with 2-mercaptoethanol to destroy 
the IgM antibody has been shown to be useful in situations 
where the level of IgM antibody will be higher than that of 
IgG antibody {Forghani et al., 1973). However, this is seldom 
the case in postnatal or congenital infection with rubella. 
Separation of the IgM fraction of serum before measuring 
antibody by hemagglutination-inhibition (HAl) has been shown 
to be a sensitive and reliable although laborious technique. 
This separation has been accomplished by sucrose density 
gradient centrifugation (Palmer et al., 1977); gel filtration 
on Sephadex G-200 {Gupta et al., 1971); affinity chromatography 
{Peterson and Sober, 1962); and removal of lgG using staphylo-
coccal protein A absorption (Ankerst et al., 1974). 
The indirect immunofluorescence and enzyme immunoassay 
methods possess certain advantages over other methods in the 
measurement of specific lgM antibody. By using a conjugated 
antihuman globulin specific for human IgM, it is possible to 
detect IgM antibody without separation of the IgG and IgM 
fractions of the test serum. Both methods are less time con-
suming and relatively easy to perform, but they have signifi-
cant sources of error which must be understood and controlled 
before the tests can be properly utilized. 
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Rubella Indirect Immunofluorescence (IIF) Test 
The first indirect immunofluorescent (IIF) staining 
technique for assay of rubella antibodies was described in 
1964 by Brown and associates. They employed chronically 
infected cell cultures of the LLC-MK2 rhesus monkey kidney 
line as a source of antigen for staining. Schaeffer et al. 
(1964) utilized infected primary cultures of African green 
monkey kidney cells. Serial dilutions of the test serum were 
applied to fixed virus-infected cells. If antibody was pre-
sent, its union with virus in the cells was detected through 
the use of fluorescein-labeled anti-human immunoglobulins. 
Although the indirect fluorescent antibody technique 
offered a much simpler and more rapid method than the neutra-
lization (Parkman et al., 1964) test for assaying of rubella 
antibodies, attempts to use the procedure on a large-scale 
diagnostic basis met with varying degrees of success. One of 
the major problems that Brown and Schaeffer faced was that of 
obtaining infected cells containing large amounts of antigen. 
The sensitivity of their technic was also dependent upon the 
use of high-titered and specific anti-human immunoglobulin 
conjugates. 
Lennette et al. (1967) developed a modified indirect 
immunofluorescent staining technique for assay for rubella 
antibodies. This procedure proved to be as sensitive as the 
neutralization test for detection of antibodies and more reli-
able than neutralization for demonstrating diagnostically 
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significant increases in antibody titer. Smears of rubella 
infected cells were employed for staining rather than infected 
coverslip cultures. Initially, the BS-C-1 line of green mon-
key kidney cells was employed, and more recently, the BHK-21 
line of baby hamster kidney cells has been found to be very 
satisfactory. With both cell lines, it was necessary to infect 
the cells with a large dose of virus to obtain maximum numbers 
of infected cells for staining. 
The indirect immunofluorescent staining technique is 
being investigated as a potential method for diagnosing pri-
mary rubella infections by demonstrating specific IgM class 
antibody. The IgM-indirect immunofluorescence test is similar 
to conventional indirect immunofluoresence tests. Human serum 
is reacted with antigen substrate and following incubation, 
the unreacted portion of the serum is rinsed from the substrate. 
Fluorescein-conjugated anti-human IgM is then added and, fol-
lowing a second incubation, the slide is again rinsed and 
examined under a fluorescent microscope. If IgM class antibody 
to rubella is present in the serum, it will combine with the 
antigens of the substrate and the fluorescein-conjugated anti-
human IgM will be bound causing fluorescence when the slide 
is examined under the microscope. 
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Rubella Enzyme Immunoassay (EIA) Test 
It was not until 1975 that Voller and Bidwell described 
the first enzyme immunoassay (EIA) method for detecting 
antibodies to rubella. The tests were carried out on Cooke 
disposable 96 well microtitration plates sensitized with 
rubella antigen. Alkaline phosphatase labeled anti-human 
globulin was used as the conjugate and p-nitrophenyl phosphate 
in diethanolamine buffer as the substrate solution. Positive 
reactions were recognized by the obvious yellow coloration in 
the wells. Voller and his associates demonstrated the validity 
of the test by assaying human sera of known hemagglutination-
inhibitionn titer and sera known to be negative for rubella 
antibody. 
The EIA test is also under investigation as a possible 
method for diagnosing primary rubella infections by demonstra-
ting IgM antibody. In the IgM-specific EIA test, the serum 
is reacted with a solid phase containing rubella antigen. 
If the serum contains antibody to rubella, the antibody will 
form a complex with the antigen. After washing unreacted 
serum from the solid phase, it is incubated with an anti-lgM-
enzyme conjugate. The conjugate will react with the IgM 
antibody-antigen complexes on the solid phase. The presence 
of enzyme on the solid phase is determined by incubating the 
solid phase in an appropriate enzyme substrate. The enzyme-
substrate reaction will result in a color change that can be 
measured in a spectrophotometer. 
CHAPTER III 
MATERIALS AND METHODS 
Serum Specimens 
Serum containing rubella antibody was obtained from a 
susceptible donor that had been vaccinated with rubella 
vaccine. Specimens from this donor were obtained before 
vaccination and at weekly intervals for four weeks after 
vaccination. Other serum specimens were obtained from the 
Serum Bank, Centers for Disease Control (CDC), Atlanta, 
Georgia, or were purchased from various commercial sources by 
the Proficiency Testing Branch, CDC. They included sera 
positive for RF, sera containing no rubella antibody, and 
sera positive for rubella antibody. 
Isolation of IgM Fraction from Serum Specimens 
A modified ion exchange chromatography method was used 
(Peterson and Sober, 1962). The modifications included the 
use of 0.05 M Tris-HCl (pH 8.0) as the starting buffer (Appen-
dix A) and Tris-HCl-0.2 M NaCl (pH 8.0) as the eluting buffer 
(Appendix A). Also, Diethylaminoethyl (DEAE) cellulose (What-
man, Inc., Clifton, New Jersey) was obtained in powder form 
and used as the ion exchanger. In addition, the barrel of a 
6-cc disposable syringe, 1.2 em in diameter was used as the 
column. The bed volume of the column was 2.0 ml. Each serum 
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s p e c i men ( 0 • 5 m 1 } was d i 1 u t e d w i t h 1 0 m 1 of the s t a rt i n g 
buffer and the pH was adjusted to 8.0 with 0.5 N HCl. The 
diluted serum was introduced over the cellulose with a Pasteur 
pipette and the column rinsed with 40 ml of starting buffer. 
Eluting buffer (5.0 ml) was then added to the column and all 
liquid was collected. The IgM-rich eluate was concentrated 5 
times (to approximately 1.0 ml) with a minicon 815 concentrator 
(American Corporation, Lexington, Massachusetts} to be later 
analyzed for rubella IgM antibody. 
The efficiency of IgM fractionation from the serum 
specimens was determined by assaying the concentrated IgG 
portion and its "parent" whole serum by using single radical 
immunodiffusion plates (Kallestad Laboratories, Inc., Austin, 
Texas). At least 95% of the IgG was removed from each sample 
and about half of the IgM recovered (Table 1). 
The IgM fractions were also assayed to determine if any 
detectable rubella IgG antibody remained by employing fluoro-
immunoassay (FIA) (International Diagnostic Technology, Santa 
Clara, California) specific for rubella IgG antibody. High-
titer, low-titer, and negative controls were included with 
each test run. All results were negative for rubella lgG 
antibody (Table 2). 
Determination of Rubella IgM Antibody in the IgM. Fraction 
The modified hemagglutination-inhibition (HAl) test 
(Palmer et al., 1977) was followed throughout Rubella Reference 
Table 1. Efficiency of IgM isolation from serum specimens. 
-·----·--
IgG Cone. (mg/dl} IgG removed IgM Cone. {mg/dO I gM recovered 
Specimen Whole serum IgM fraction (%) Whole serum I gM fraction (%) 
---
A 680 27 96.0 280 180.3 64.4 
B 700 29 95.9 300 185.7 61.9 
c 580 27 95.3 82 46.5 56.7 
D 820 < 18 > 97.8 125 86.1 68.9 
E 390 < 18 > 95.4 74 59.5 80.4 
..... 
F 1225 29 97.6 295 165.4 56.1 m 
G 1250 32 97.4 82 40.0 48.8 
H 1450 37 97.5 170 88.3 51.9 
I 700 29 95.9 68 32.5 47.8 
J 1775 37 97.9 205 130.0 63.4 
K 860 < 18 > 97.9 245 122.2 49.4 
L 500 < 18 > 96.4 54 28.6 52.9 
M 1100 37 96.9 170 95.2 56.0 
N 1300 29 97.8 170 83.0 48.8 
Rubella IgM Anti-
body Specimen 1300 36 97.2 105 68.0 64.8 
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Table 2. Rubella IgG antibody titers of the lgM fractions 
and their corresponding whole serum using 
fluoroimmunoassay (FIA). 
FIA titer 
Specimen Whole serum IgM fraction 
A 156 <6 
B >200 <6 
c 149 <6 
0 104 <6 
E 37 <6 
F < 6 <6 
G >200 <6 
H 45 <6 
I >200 <6 
J 165 <6 
K >200 <6 
L 50 <6 
M >200 <6 
N 186 <6 
Rubella IgM 
Antibody Specimen < 6 <6 
Note: titers <6 are considered negative. 
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Hemagglutination Antigen (Lot number 79-0024) was obtained 
from the Biological Products Division, Centers for Disease 
Control (CDC). Nonspecific inhibitors were removed from the 
serum using heparin-MnCl2 (Flow Laboratories, Rockville. Mary-
land). Hepes-saline-albumin-gelatin (HSAG) buffer (Flow Labo-
ratories) was used as the diluent; and human 0 cells that were 
washed in dextrose-gelatin-veronal (DGV) buffer (Flow Labora-
tories) were used as indicators in the test. The cells were 
trypsinized in a 1% trypsin solution (Difco Laboratories, 
Detroit, Michigan) and suspended in HSAG (0.25%). High, low, 
and negative rubella controls were included. The IgM fraction 
of the specimen taken from a susceptible donor 4 weeks after 
vaccination was positive for rubella antibody, and all other 
fractions were negative (Table 3). 
Determination and Quantitation of IgM Rheumatoid Factors {RF) 
in the Serum Specimens 
The latex agglutination-rheumatoid factors (RF) slide 
t est ( C a 1 b i o c hem-Be h r i n g , La J o 1 1 a , C a 1 i for n i a ) was to screen 
sera for RF. Positive specimens were separated into lgG and 
IgM fractions and rescreened for RF. Parent sera that were 
positive in the lgM fraction and negative in the lgG fraction 
were considered to possess only IgM RF. IgM RF titers were 
obtained with serial two-fold dilutions of the serum, beginning 
at a 1:20 dilution (Table 4). 
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Table 3. Rubella antibody titers of the lgM fractions and 
their corresponding whole serum using hemaggluti-
nation-inhibition (HAl). 
HAl titer 
Specimen Who 1 e serum IgM fraction 
A 128 <8 
B 128 <8 
c 64 <8 
D 64 <8 
E 64 <8 
F < 8 <8 
G 32 <8 
H 8 <8 
I 128 <8 
J 32 <8 
K 512 <8 
L 32 <8 
M 256 <8 
N 64 <8 
Rubella lgM 
Antibody Specimen 16 8 
Note: titers <8 are considered negative. 
Table 4. Determination and titration of IgM rheumatoid factors {RF) using 
latex agglutination. 
---------------·---·-----·------------------------------
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Prepar~tion of Samples 
Samples for distribution in the special study were pre-
pared by combining the serum species described above and were 
adjusted with sera non-reactive for rubella antibody and 
rheumatoid factors (RF) to projected values shown in Table 5. 
The serum pools were filtered (0.22-micron filters) and were 
then dispensed aseptically as 0.6 ml aliquots into 3.0 ml 
vials. The vials were stoppered, crimped, and then labeled 
as shown in Table 5. The samples were stored at 4 C. 
Experimental Design 
Sixty volunteer laboratories were selected from the 
Proficiency Testing Program of the Centers for Disease Control 
( CD C ) to p a rt i c i pate i n t he eva 1 u at i on (A p pen d i x B ) • The 
laboratories were selected on the basis of their past per-
formance in the Proficiency Testing Program. Thirty were 
asked to test for and quantitate rubella antibodies (IgG and/or 
IgM) using hemagglutination-inhibition, indirect immunofluore-
scence, or enzyme immunoassay, and 30 were asked to test for 
and quantitate RF. The laboratories were also asked to report 
kit or reagent manufacturer. 
Samples for the shipment were packed in styrofoam mail-
; ng containers along with the appropriate report forms and 
instructions (Appendices C and D), and were shipped at ambient 
tempe r a t u r e to t he p a rt i c i pat i n g 1 abo r a to r i e s on M a r c h 3 0 , 
1982. Acceptable sample stability under these conditions has 
Table 5. Sample numbers and projected titers. 
-·--------
Serum pool HAl antibody titer Latex agglutination titer 
(Sample number} Rubella IgG Rubella IgM lgM RF 
RS1-A01 16 0 40 
RS1-A02 16 0 640 
RS1-A03 0 16 0 
RS1-A04 64 0 160 
RS1-A05 64 0 40 
N 
RS1-A06 8 0 640 N 
RS1-A07 128 0 40 
RS1-A08 0 0 0 
RS1-A09 32 0 320 
RS1-A10 128 0 80 
HAl = Hemagglutination-inhibition 
RF = Rheumatoid factors 
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been demonstrated through internal quality control and from 
the results of previous Proficiency Testing surveys conducted 
by CDC. 
Statistical Methods 
Statistical analysis of results received from the labo-
ratories was done by using previously described methods appro-
priate to log-normally distributed data (Taylor et al., 1979). 
Correlation regression analysis was done according to the 
methods of Freund (1976). 
CHAPTER IV 
EXPERIMENTAL RESULTS 
Of the 30 laboratories to whom samples were mailed, 
three reported results for rubella IgM antibody using commer-
cially prepared indirect immunofluorescence {IIF) or enzyme 
immunoassay {EIA) test kits (Table 6). Although all samples, 
except RS1-A03, were previously determined to contain no 
rubella IgM antibody, positive (false-positive) results were 
reported for 5 of the 10 samples tested by each of two labora-
tories that used I IF. Reported titers ranged from 8-32 for 
one laboratory and 8-64 for the other. There were no false-
positive results reported by the laboratory that used EIA. 
A common feature of the 5 samples that produced false-
positive results for rubella IgM antibody was the presence of 
bot h rube 11 a I g G ant i bod i e s and I g M rheum at o i d factors ( R F ) • 
Of the ten samples tested, all except RS1-A03 and RS1-A08 
were prepared from sera that were previously determined to 
contain rubella IgG antibody with use of fluoroimmunoassay 
(FIA). In addition, IgM RF was added and detected in all 
samples except RS1-A03 and RS1-A08 with use of latex aggluti-
nation in conjunction with ion exchange chromatography. Sample 
RS1-A03 was prepared from serum taken from a susceptible 
donor four weeks after vaccination with rubella vaccine. 
This sample was the only sample that was positive for rubella 
24 
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Table 6. Reported rubella IgM antibody results. 
Titer 
Sample Number IIF p gM) EIA {IgM) 
Lab A Lab B 
RS1-A01 <8 <8 
RS 1- AO 2 <8 32 
RS1-A03 <8 <8 
R S 1- A04 8 32 
RS1-A05 <8 <8 
RS 1-A06 <8 <8 
RS1-A07 8 8 
RS1-A08 32 <8 
RS1-A09 8 16 
RS1-A10 8 64 
IIF (IgM} = indirect immunofluorescence (specific for IgM} 















antibody in the IgM fraction. 
Although false-positive results for rubella IgM antibody 
were reported for 5 samples that contained both rubella IgG 
antibody and IgM RF, there were also 3 samples that shared 
this common feature and did not produce false-positives. The 
difference between those samples that contained both rubella 
IgG antibody and lgM RF was the reactivity level of each in 
the sample. Rubella hemagglutination-inhibition (HAl) titers 
received from 22 of 30 laboratories were used to estimate the 
concentration of rubella IgG antibody for each sample (Table 
7). Although the HAl test is not specific for IgG antibody, 
its use to estimate rubella IgG antibody concentrations was 
possible because all samples, except RS1-A03 were negative 
for rubella lgM antibody. In addition, all samples except 
RS1-A03 and RS1-A08 were determined to contain rubella IgG 
antibody with use of FIA. Therefore, rubella IgG antibody 
was the predominant class of antibody present. Also, quan-
titative RF results were received from 28 or 30 laboratories 
that used latex agglutination to assay the samples (Table 8). 
The latex agglutination test primarily reflects the amount of 
IgM RF because of the efficacy of IgM molecules in agglutination 
reactions. In addition, only the RF of the IgM class was 
added to the samples. Therefore, results reported by the 
laboratories represent IgM RF concentrations. 
The geometric mean (Xg) concentration of both rubella 
IgG antibody and IgM RF was determined for each sample and is 
Table 7. Reported rubella hemagglutination-inhibition (HAl) antibody titers. 
Rubella antibody titer 
Lab 
Code RS1-A01 RS1-A02 RS1-A03 RS1-A04 RS1-A05 RS1-A06 RS1-A07 RS1-A08 RS1-A09 RS1-A10 
D 32 32 16 128 128 16 256 8 64 256 
E 32 32 8 64 128 16 256 <8 32 256 
F 64 64 32 128 128 32 512 16 64 256 
G 16 32 8 32 64 8 128 <8 16 256 
H 32 64 16 64 64 16 256 <8 32 256 
I 32 64 32 128 128 16 256 8 64 512 
N 
-...J 
J 16 32 8 64 256 8 512 <8 32 512 
K 16 32 16 64 64 8 256 <8 32 256 
L 32 32 16 64 128 16 512 <8 64 1024 
M 16 32 16 64 64 16 128 <8 32 256 
N 128 128 32 128 256 64a 512 32a 128 512 
0 32 64 16 128 128 16 256 <8 32 256 
p 32 64 8 64 64 16 128 <8 32 256 
Q 16 32 8 64 64 16 128 <8 32 128 
a = excluded from statistical calculations (outlier) 
Table 7 (Continued). 
--------
Rubella antibody titer 
Lab 
Code RS1-A01 RS1-A02 RS1-A03 RS1-A04 RS1-A05 RS1-A06 RS1-A07 RS1-AOS RS1-A09 RS1-Al0 
R 32 32 16 12S 12S 16 1024 <S 64 1024 
s <sa sa <S 16 32a <S 64 <S 16 12S 
T 12S 256a 64a 512a 256 64a 1024 16 12S 204sa 
u 10 10 10 20 40 10 so <10 20 so 
v 32 32 16 64 12S 16 512 <S 32 256 
w 40 40 20 so 160 10 320 <10 40 320 
"' 00 
X 10 20 <10 40 so <10 160 <10 20 160 
y 40 so 20 80 80 40 320 <10 so 320 
.a = excluded from statistical calculations (outlier} 
Table 8. Reported IgM rheumatoid factors concentration using latex agglutination. 
-----·--·-- ----
Rheumatoid factors concentration (IU/ml) 
lab 
Code RS1-A01 RS1-A02 RS1-A03 RS1-A04 RS1-A05 RS1-A06 RS1-A07 RS1-A08 RS1-A09 RS1-A10 
A2 61 62 31 62 31 31 <20b 125 <20b 31 
B2 126 126 250 62 126 62 
C2 62 62 31 125 31 62 16 <20b 125 31 
02 250 1000 500 500 500 
E2 250 250 <2ob 500 31 250 16 <2ob 500 125 
F2 125 125 <16 250 63 125 31 <16 250 125 
"' \0 
G2 10ooa 2oooa 1000a woo a woo a 
H2 125 250 63 
12 63 125 <8 125 8 63 <8 <8 125 15 
J2 63 63 125 63 250 16 
K2 125 250 250 250 250 125 
l2 63 125 125 31 63 
a =was not included in statistical calculations (out 1 i er). 
b = result reported as titer and was not included in statistical calculations. 
- - laboratory reported qualitative negative results. 
IU/ml =International units per ml. 
Table S (Continued). 
Rheumatoid factors concentration (IU/ml) 
Lab 
Code RS1-A01 RS1-A02 RS1-A03 RS1-A04 RS1-A05 RS1-A06 RS1-A07 RS1-AOS RS1-A09 RS1-A10 
M2 <2ob 125 <2ob 125 <20b 31 <20b <2ob 125 <20b 
N2 63 125 31 125 31 63 31 31 63 63 
02 30 60 <S 60 <S 30 <S <S 60 20b 
P2 31 63 63 31 63 63 31 
Q2 500 1000 <20b 500 5ooa 500 125 <2ob 500 125 
R2 20b 20b <2ob 20b <20b 20b <20b <20b 20b 20b w 
0 
S2 62 250 <16 500 <16 250 16 s 250 s 
T2 250 250 <31 250 31 125 16 <16 250 16 
U2 31 63 125 31 31 s 
V2 31 63 63 s 63 125 31 
W2 sob 160b <20b 32ob <20b sob <20b <20b 160b 20b 
X2 sob 160b <20b 16ob <20b sob <20b <20b 16Qb 40b 
a = was not included in statistical calculations {out 1 i er). 
b = results reported as titer and was not included in statistical calculations. 
- = laboratory reported qualitative negative results. 
IU/ml =International units per ml. 
---------------------~~~~~~~~~~-~ ~-~- -
Table 8 (Continued). 
Rheumatoid factors concentration (IU/ml) 
Lab 
Code RS1-A01 RS1-A02 RS1-A03 RS1-A04 RS1-A05 RS1-A06 RS1-A07 RS1-A08 RS1-A09 RS1-A10 
V2 125 125 125 
Z2 63 125 125 63 125 
A3 63 125 <20b 125 <20b 63 <20b <20b 63 31 
B3 125 250 125 125 250 
a =was not included in statistical calculations (outlier). 
b = result reported as titer and was not included in statistical calculations. 
- - laboratory reported qualitative negative results. 
IU/ml = International units per ml. 
32 
shown in Table 9. Reported rubella HAl titers that were more 
than two geometric standard deviations {Sg) above or below 
the Xg titer of the pooled data for each sample were considered 
outliers and were excluded from additional statistical calcu-
lations. A 95% confidence interval was established for each 
sample. In addition, RF results that were not reported in 
international units per ml {IU/ml) were excluded from statis-
tical calculations. Quantitative RF outliers were also exclu-
ded. For sample RS1-A03 and RS1-A08, more than 85% and 89% 
of the laboratories, respectively, reported less than 16 IU/ml, 
titers less than 20, or qualitatively negative results. There-
fore, quantitative results indicating the presence of lgM RF 
in those samples were considered outliers. A 95% confidence 
interval was established for those samples that did contain 
IgM RF. 
The occurrence of false-positive rubella IgM antibody 
results correlated to Xg concentrations of lgM RF and Xg 
titers of rubella lgG antibody was significant (r = -0.96, 
p<0.05) {Figure 1). For those samples that contained lgM RF 
and rubella IgG antibody and were reported to contain rubella 
IgM antibody (false-positive), the Xg titer of rubella IgG 
antibody was low and the Xg concentration of lgM RF was high. 
Conversely, false-positive results were reported for those 
samples with a high Xg titer for rubella IgG antibody and a 
low Xg concentration for lgM RF {Figure 2). The optimal concen-
tration of rubella IgG antibody and lgM RF that must be simul-
taneously present in order to cause false-positives would 
Table 9. Summary statistics for reported rubella hemagglutination-inhibition antibody titers and 
rheumatoid factors latex agglutination concentration. 
Sample Number Rubella Rheumatoid factors 
Xg Sg Var. 95% CI Xg Sg Var. 95% CI 
RS1-A01 29.2 1.982 .974 21.4- 39.9 83.9 2.185 1.271 58.8-119.8 
RS1-A02 39.8 1.741 .639 30.7- 51.6 140.2 2.190 1.279 100.7-195.2 
RS1-A03 13.2 1. 783 .696 10.1- 17.2 NA NA NA NA 
RS1-A04 66.8 1.801 .720 51.1- 87.3 161.9 1.962 .945 121.8-215.2 
RS1-A05 106.0 1.683 .564 83.6-134.3 18.9 2.384 1.571 10.5- 33.9 
RS1-A06 13.1 1. 729 .624 10.1- 16.9 85.5 2.407 1.605 57.9-126.2 
RS1-A07 266.6 2.111 1.162 191.4-371.3 17.1 2.872 2.316 7.6- 38.5 
RS1-A08 NA NA NA NA NA NA NA NA 
RS1-A09 40.2 1.809 .731 30.9- 52.3 141.0 2.166 1.244 100.9-196.9 
RS1-A10 285.3 1.858 .798 215.2-378.2 38.8 2.545 1.818 23.6- 63.8 
Xg = geometric mean (base 10) 
Sg = geometric standard deviation (base 10) 
Var. = variance (base 2) 
Cl = confidence interval 
NA = negative sample 
w 
w 
+=false-positive rubella IgM antibody result 
Figure 1. Occurrence of false-positive rubella IgM indirect 
immunofluorescence (IIF) antibody results correlated 
to geometric mean (Xg) concentrations of IgM rheuma-
toid factors (RF) and Xg titers of rubella IgG anti-
body. The solid line represents the regression 




















0 ... 64 
at .s 
31 62 125 
Log
10 
Geometric mean concentration, lgM rheumatoid factors (IU/ml) 
+=false-positive rubella IgM antibody result 
=negative rubella IgM antibody result 
Figure 2. Occurrence of false-positive rubella IgM antibody 
results, with use of indirect immunofluorescence 
(IIF), related to geometric mean (Xg) concentrations 
of IgM rheumatoid factors (RF) and Xg titers of 
rubella IgG antibody. 
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Log1 0 Geometric mean titer, rubella lgG antibody 
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require additional investigation. 
Sample RS1-A08 was reported to have a rubella IgM anti-
b o dy t i t e r o f 3 2 by o n e of t he two 1 a b o r a t o r i e s u s i n g I I F • 
Seventeen (77.3%) laboratories using HAI reported negative 
results for this sample. No IgM RF was present, however. 
Results reported for this sample were, therefore, not included 
in correlation regression analysis. Only those samples that 
produced false-positive results and contained both rubella 
IgG antibody and IgM RF were analyzed. An explanation for 
the discrepancies that exist between results reported for 
sample RS1-A08 would require additional investigation and is 
beyond the scope of this research. There were no false-posi-
tive results reported by the laboratory that used EIA. How-
ever, additional investigation including a larger number of 
laboratories would be necessary in order to determine the 
interference potential of IgM RF in the EIA test. 
Sample RS1-A03 was reported to have no rubella IgM 
antibody with use of IIF or EIA. This sample was prepared 
from serum taken from the susceptible donor four weeks after 
vaccination with rubella vaccine. The IgM fraction was posi-
tive for rubella antibodies using HAI. A probable explanation 
for why these differences occurred between methods is the 
immunoglobulin specificity of the tests, however, additional 
research would be necessary. 
CHAPTER V 
DISCUSSION 
The most effective method for diagnosing early rubella 
infections has been to simultaneously test acute- and convale-
scent-phase sera with use of the hemagglutination-inhibition 
(HAI) test. A significant rise in antibody titer would be indi-
cative of a recent infection. In cases involving pregnancies, 
however, it is necessary to distinguish between an early primary 
infection which puts the fetus at risk of being infected and 
reinfection which poses no threat to the fetus. A useful tool 
to be utilized in making this distinction is the antibody re-
sponse to a primary rubella virus infection. IgM class antibody 
is the first antibody class to appear and does not reappear upon 
subsequent infections. Therefore, its presence in the serum 
is indicative of a primary rubella infection. 
The HAI test has also been used effectively to detect the 
presence of IgM class antibody to rubella. However, the tech-
nique is tedious and time-consuming. First, the serum should 
be treated with protein A to remove IgG antibodies or frac-
tionated into IgG and IgM fractions. The treated serum or IgM 
fr~ction must then be tested for rubella antibody activity. A 
positive reaction would be indicative of the presence of rubella 
IgM antibody and a primary infection. 
The indirect immunofluorescence (IIF) and enzyme immuno-
37 
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assay (EIA) test are potentially capable of diagnosing early 
rubella infections by demonstrating rubella IgM antibody. Both 
methods are relatively easy to perform and are less time 
consuming than the HAl test. There is no requirement for serum 
treatment of fractionation. But as reported by Shirodaria et 
al. (1973), secondary fluorescent staining of virus antigens by 
IgM rheumatoid factors (RF) and fluorescent conjugated anti-IgM 
may lead to false-positive test results. Therefore, erroneous 
interpretations of the immune status of expecting mothers could 
result. Those misinterpretations could possibly lead to unde-
sirable abortions. 
Results of this study showed that IgM RF has the potential 
to cause false-positive reactions in the IIF assay for rubella 
IgM antibody. Those samples that were reported to have rubella 
IgM antibody (false-positive) were also reported to have either 
a high concentration of IgM RF and a low rubella IgG antibody 
titer or a low IgM RF concentration and a high rubella IgG 
antibody titer. The occurrence of false-positives in the IIF 
test, due to IgM RF, was found to be significant. However, a 
more detailed investigation is required to determine the optimal 
concentration of IgM RF and rubella IgG antibody that must be 
simultaneously present to cause false-positives. Additional 
investigation including a larger number of laboratories would 
be necessary to determine if IgM RF can cause false-positive 
reactions in the EIA test. 
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Although IgM RF is potentially capable of producing false-
positive rubella IgM results in the IIF test, it should not be 
ruled out as a possible substitute when the HAl test cannot be 
used. Instead, when the test results indicate the presence of 
rubella IgM antibody, the serum should be screened for IgM RF. 
If IgM RF is present, the serum should be treated with aggregated 
IgG (Meurmann and Ziola, 1978} to remove RF or protein A (Ankerst 
et al., 1974} to absorb IgG. The serum should then be reassayed 
using the IIF test. The presence of rubella IgM antibodies, 




The potential of I gM rheumatoid factors (RF) to cause 
false-positive reactions in the indirect immunofluorescence (IIF) 
and enzyme immunoassay (EIA) tests for rubella lgM antibody was 
evaluated. False-positive reactions in the IIF test were found 
to occur in two basic conditions: (1) when the test serum con-
tained a high concentration of lgM RF with a relatively low con-
centration of rubella IgG antibody; (2} high concentration of 
rubella IgG antibody with a relatively low concentration of 
IgM RF. The optimal relative concentration of both rubella IgG 
antibody and IgM RF that must be simultaneously present to cause 
false-positives would require additional investigation. Also, 
additional investigation involving a larger number of laborato-
ries would be necessary to determine whether IgM RF can cause 
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A p p E N D I c E s 
APPENDIX A 
?reparation of Reagents 
Starting Buffer {0.05 M Tris-HCl, pH 8.0) 
HCl {26.8 ml, 1M) and Tris (250 ml, 0.2 M) were added 
to deionized water (final volume 1.0 liter). 
Eluting Buffer (Tris-HCl-0.2 M NaCl, pH 8.0) 
Tris (12.11 g, 1 M) and NaCl (11.69 g, 0.2 M) were 
dissolved in deionized water (final volume 1.0 liter): 
1 N HCl was used to adjust pH to 8.0. 
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APPENDIX B 
Volunteer Laboratories Selected from the Centers for 
Disease Control Proficiency Testing Program to Participate 
in the Special Study 
ALA. Dept. of Public Health 
Clinical Laboratory Administration 
University Drive 
Montgomery, Alabama 36130 
State of California Dept. of Health 
Microbial Diseases 
2151 Berkeley Way 
Berkeley, California 94704 
Reference Laboratory 
1011 Rancho Conejo Blvd. 
Newbury Park, California 91320 
Diagnostic Immunology Laboratory 
Medical Group, Inc. 
805 Laveta Ave. 
Orange, California 92668 
Bureau of Laboratories 
Arkansas Dept. of Health 
4815 W. Markham St. 
Little Rock, Arkansas 72201 
Clinical Immunology Labs., Inc. 
2122 Granville Ave. 
Los Angeles, California 90025 
Western Pathology Laboratory 
Western Laboratories 
2945 Webster St. 
Oakland, California 94609 
National Health Labs., Inc. 
7355 Carroll Road 
San Diego, California 92121 
49 
Sumelin Memorial Lab. 
D.N. Sharp Memorial Community 
Hospital 
7901 Frost St. 
San Diego, California 92123 
Bio-Science Laboratories 
7600 Tyrone Avenue 
Van Nuys, California 91405 
Institute of Lab Science 
4987 Olives Park Drive 
Unit 5 
Ventura, California 93003 
Denver General Hospital 
City and County of Denver 
Dept. of HLTH 
West 6th Avenue & Cherokee St. 
Denver, Colorado 80204 
Delaware Dept. of HLTH and 
Social SVCS. Div. of Public 
Health Laboratory 
Jesse S. Cooper Main Bldg. 
Capt. Sq. 
Dover, Delaware 19901 
International Diag. Technology 
2986 Oakmead Village Court 
Santa Clara, California 95050 
Clinical Laboratory Services 
Division 3M Corporation 
1899 Palma Drive 
Ventura, California 93002 
Memorial Hospital Clin. Lab. 
1400 East Boulder 
Colorado Springs, Colorado 80909 
Veterans Administration Hospital 
1055 Clermont St. 
Denver, Colorado 80220 
Professional Clinical Labs, Inc. 
1701 Shallcross Ave. 
Wilmington, Delaware 19806 
Central Med Lab., Inc. 
1801 Coral Way 
Miami, Florida 33145 
V. A. Hospital 
1201 Northwest 16th Street 
Miami, Florida 33125 
Immunology Lab. - Room F125 
1364 Clifton Road, N.E. 
Atlanta, Georgia 30322 
The Medical Center 
710 Center Street 
Columbus, Georgia 31902 
John L. Hutcheson Memorial 
Tri-County Hospital 
100 Gross Crescent Drive 
Fort Oglethorpe, Ga. 30741 
Rush Presbyterian-Saint Luke•s 
Me d. 
OCLS Clinical Immunology 
1753 West Congress Parkway 
Chicago, Illinois 60612 
Cordis Laboratories 
2140 North Miami Avenue 
Miami, Florida 33127 
Dept. of HLTH & Rehabilitative 
Sers. Office of Lab. Services 
P. 0. Box 210 
Jacksonville, Florida 32231 
50 
ICL of Georgia, Inc. 
Medical Reference Labs. 
633 West 19th Street 
Columbus, Georgia 31901 
Veterans Hospital 
1670 Clairmont Rd., N.E. 
Decatur, Georgia 30033 




Valdosta, Georgia 31601 
University of Illinois Hospital 
Clinical Laboratory, Room 201 
840 S. Wood Street 
Chicago, Illinois 60612 
State of Illinois Dept. of 
Public Health Div. of Labs. 
2121 West Taylor Street 
Chicago, Illinois 60612 
Highland Park Hospital 
718 Glenview Avenue 
Highland Park, Ill. 60035 
Hinsdale Sanitarium and 
Hospital 
120 N. Oak Street 
Hinsdale, Ill. 60521 
Abbott Diagnostics Division 
Abbott Laboratories 
D926 AP2 
North Chicago, Ill. 60064 
Indiana State Board of Health 
Bureau of Laboratories 
1330 West Michigan St. 
Indianapolis, Indiana 46206 
New Jersey State Dept. of 
Health 
John Fitch Plaza 
CN 360 
Trenton, New Jersey 08625 
Evanston Hospital 
Dept. of Microbiology 
2650 Ridge Avenue 
Evanston, Ill. 60201 
Veterans Administration Hospital 
Hines, Ill. 60141 
Veterans Administration Medical 
Center 
North Chicago, Ill. 60064 
Lutheran General Hospital 
Immunology Lab. 
1775 Dempster St. 
Park Ridge, Ill. 60068 
Iowa State Hygienic Lab. 
University of Iowa 
Iowa City, Iowa 52240 
Kansas Dept. HLTH. & 
Environment 
Office of Labs and Research 
Forbes Building #740 
Topeka, Kansas 66620 
Dept. for Human Resources 
Bureau for Health Services 
275 East Main St. 
Frankfort, Kentucky 40601 
Electro-Nucleonics Lab, Inc. 
4815 Rugby St. 
Bethesda, Maryland 20014 
Minnesota Dept. of Health 
University Campus 
717 Delaware St., S.E. 
Minneapolis, Minnesota 55440 
State of New Mexico 
Scientific Lab. Div. 
700 Camino De Salud, N.E. 
Albuquerque, New Mexico 87106 
Presbyterian Hospital 
Clinical Microbiology Service 
622 W. 168th Street 
New York, New York 10032 
51 
Ohio Dept. of Health 
1571 Perry St. 
P. 0. Box 2568 
Columbus, Ohio 43216 
Louisiana Bureau of Labs. 
7th Floor 
325 Loyola Avenue 
New Orleans, La. 70112 
M. A. Bioproduct 
Bldg. 1000 
Biggs Ford Rd. 
Walkersville, Md. 21793 
Montana State Dept. of Health 
Laboratory Division 
Helena, Montana 59601 
Laboratory Medicine Institute 
Div. of Labs & Resch. 
N. Y. St. Dept. Health 
Empire State Plaza 
Albany, New York 10016 
North Carolina State Board 
of HLTH 
Lab. Div. 
P. 0. Box 28047 
Raleigh, North Carolina 27611 
Oklahoma State Dept. of Health 
Div. of Labs. 
P. 0. Box 24106 
Oklahoma City, Oklahoma 73124 
Pennsylvania Dept. of Health 
Bureau of Labs. 
Pickering Way & Welsh Pool Rd. 
Lionville, Pennsylvania 19353 
Microbiological Research Corp. 
40 West 500 South 
Bountiful, Utah 84010 
Vermont State Public HLTH Lab. 
115 Col chester 
Burlington, Vermont 05401 
S. D. State of Health 
Health Laboratory Bldg. 




Salt Lake City, Utah 84148 
State of Washington Dept. of 
Social and Health Service 
1409 Smith Tower 
Seattle, Washington 98104 
APPENDIX C 
Report Forms and Instructions Mailed to 
Laboratories Selected to Assay for Rubella Antibodies 
•'U'IIflt 
.... •" "~. 
Public Health Service • . .fit~~ OErARTMENT OF UEALTtl ~ til!MAN SERVICES 
\~~\-________________________________________ _ 
'• ...... t Centers for Disease Control 
Atlanta, Georgia 30333 
Participants 
CDC Proficiency Testing Program 
Rubella Serology Special Study 
PLEASE READ AND FOLLot-7 THE INSTRUCTIONS CAREFULLY: 
!-larch 31, 1982 
This shipment for the Rubella Serology Special Study consist of 10 serum 
samples. The tests to be performed on these samples are given in the 
instructions. 
If tests are performed in different parts of the laboratory, transfer 
all results to the·appropriate•report form before submitting your 
report. 
The srumples have been tested and found to be negative for Hepatitis B 
surface antigen (HBsAg); however, negative test results do not assure 
the "absence" of the agent responsible for causin~ hepatitis. Therefore, 
the samples should be handled with the same precautions that are applied 
to processin~ your patient samples, namely, that etiologic agents should 
be presumed to be present. 
If you have questions concerning this shipment, contact the Specimen 
Coordinator (Person-to-Person) at (404) 329-3871. 
Report forms should be returned to CDC no later than April 14, 1982. 
Please use the attached return address envelope to avoid delay in mail 
delivery. 
' 
DEPARTMENT OF HEALTH AND HUMAN SERVICES 
.. 
PUBLIC HEALTH SERVICE 
CENTERS FOR DISEASE CONTROL 
uureau of L.abor•tor& .. 
•u•nu, Georgi• 30333 
PROFICIEN.CY TESTING: RUBELLA SEROLOGY 
SPECIAL STUDY .. 
TEST HETHODOLOGY 
LABORATORY CODE NUMBER I 
Test Performed By: (Please Print) 
9·12 13-14 15 
8101 33 1 
(16·17) 
NDIRECT IMMUNOFLUORESCENCE UIFI 1)-lgM · 2)-IgG 
Ate all rneents obtained as a kit? 10 Yes 2 0 No 
3) ( I ) 
- (26-27) 
- IgG IgM not specific for IgG or I21't 
1281 
Antigen Source: (Enter manufacturer code number and name) 
[[]------------------------
Conjugate Source: (Enter manufacturer code number and name) 
[]]'---------------------
Dilutions tested (circle and complete one) 
1, Twofold from 1: 3. Fourfold from 1: 5~ Single dilution 1 :-------
4. Selected dilutions (not serial dilutions) 6. Other: specify -------
2. Tenfold from 1:--------
Minimum Significant Titer: (Circle one) 1. <10 2. 10.39 3. 4().160 4. >160 5. Change in titer required 
Controls Used: !Circle no more than three). 
1, Pos. high titer 




ENZYUE UiMUNOASSAY (EIA) 1)-IgG 2)-I;M----1)-(IgG/Ig.'i) ~specific 
Are all reagents obtained as a kit l.L___jYes 2. l___j No 
Antigen Source: (Enter manufactor code number and name) 
for IgG or IgM 
I I ! ________________________________ _ 
1
conj,gati Source: (Enter manufacturer code number and mane) 
Controls Used: (Circle no more than three) 
1. Pos. high titer 3. Negative 
2. Pos. low titer 4. Other: Specify ---------------------------
Number of standards used: 
Concentration of standards used: 








RUBELLA SEROLOGY SPECIAL STliDY 
TESTING INSTRUCTIONS 
1. If your laboratory performs assays for IgG- or IgM-specific rubella 
antibody, report results for those analtyes Q_nly_ if you employ 
indirec~ immunofluorescence or enzyme immunoassay. 
2. If you do not assay for specific antibody then test the samples by 
the method(s) routinely used in your laboratory. 
PROCEDURE GLOSSARY 
Agglutination Test 
02 Hemagglutination - Inhibition (HI) 
03 Passive (Indirect) Hemagglutination (PRA,IRA) 
Labeled Irnmunoassays 
Conjugated anti-Human (IgG) globulin 
04 Indirect Immunofluorescence (IIF,IFA) -anti-rubella (IgG) 
OS Enzyme Immunoassay (EIA,ELISA) - anti-rubella (IgG) 
06 
07 
Conjugated anti-Human (IgM) globulin 
Indirect Immunofluorescence (IIF,IFA) -anti-rubella (1~1) 
Enzyme Immunoassay (EIA,ELISA) - anti-rubella (IgM) 
Conjugated anti-Human globulin 
08 Indirect Immunofluorescence (IIF,IFA) - rubella.antibodies 
09 Enzyme Immunoassay (EIA,ELISA) - rubella antibodies 
10 Fluoroimmunoassay (FlAX) - . rubella antibodies 
11 Other, specify -----------------------------------------------
EXAMPLES FOR USING PROCEDURE GLOSSARY (Pro. Code) 
Test 
H~nagglutination - Inhibition (HI) 
Indirect Immunofluorescence (IIF,IFA)- anti-rubella 
Indirect Immunofluorescence (IIF,IFA) - anti-rubella 
Enzyme Immunoassay (EIA,ELISA) - anti-rubella (IgH) 













1. Be sure to enter your correct laboratory code number in the space provided. 
2. Two columns are provided for results. 
enter results in the left column only. 
should be entered in the right column. 
performed, photo~opy the form and enter 
If only one procedure is performed, 
Results from a second procedure 
If more than two procedures are 
results on the copy. 
3. Enter results as whole numbers. For eximpli enter 00320 NOT 1:320 or 
1/320. Fill in leading zeros. f()1r()l 3 f'2l f()l Round decimals to the 
nearest whole number. ~~ L:_j~ 
4. For Negative or Non-reactive results: 
Report either qualitative negative or Prefix 3 and the lowest detectable 
level. If you normally report quantitative results, report Prefix 3 
(less than) and the lowest dilution tested. For "less than 20" - enter 
"3" in the box under PREFIX and 00020 in the boxes for quantitative results. 
DO !Q! REPORT ALL ZEROS • 
5. Report qualitative results as negative only if the lowest dilution tested is 
negative; do not use qualitative results to indicate the significance of a 
quantitative result. 
6. For Indefinite Positive Results: 
If a result is "greater than" or "equal to or greater than" the highest 
level normally tested, enter the highest level tested in the quantitative 
result and in the PREFIX box, enter"l" for "greater than" or "2" for "equal 
to or greater than." Leave the PREFIX box blank if an endpoint is obtained. 
7. ENTER A PROCEDt~E CODE FOR EACH RESULT. Use the Procedure Glossary to find 
the number for the procedure used. DO NOT E~TER THE }~~urACTURER CODE FOR 
THE PROCEDURE CODE. -- --
8. Enter all results on a single set of forms and return all forms in one 
envelope to ensure proper credit. 
9 • DI:ADLI't-.~: 
Results for this shipment must be postmarked by April 14, 1982. 
MANUFACTURER - CODE LIST 




04 Antibodies Inc. 
.. 
OS Atlantic Antibodies 




14 Bio Diagnostics 
15 Bioquest - (BBL) 
16 Bioware 
17 Bio Dx 
21 Canalco 
22 Cappell 
23 Clinical Assays 
24 Cooke 
25 Cordis 
26 Clinical Sciences Inc. (CSI) 
31 Dade 
32 Difco 








48 Hynson Wescott Dunning 
51 Industrial Biological Laboratories (IBL) 
52 ICL Scientific 
53 International Diagnostic Technology (IDT) 
56 Kallestad 
61 Laboratory Diagnostics 
63 Lee 
64 Linbro 
66 M.A. Bioproducts 
67 Heloy 
68 Microbiological Research Corp. 
69 lUllipore 
Code No. Manufacturer 
71 New England Nuclear 
72 North American Biologicals 



















97 Local Manufacture 
using laboratory) 
98 Noncommercial 
99 Other, specify 
(prepared by 
------
• DEPARTMENT OF HEALTH AND HUMAN SERVICES 
PUBLIC HEALTH SERVICE 
CENTERS FOR DISEASE CONTROL 
BUREAU OF LABORATORIES 
ATLANTA, GEORGIA 30333 
. PROFICIENCY TtSTING:RUBELLA SEROLOGY 




[] I I I (9·10) (11·121 l3 I I LABORATORY I I I I I 81 33 1 I 1 1 I I 1 CODE NUMBER TIC 
TEST RESULT RESULT 
CODE SAMPLE QUAL. QUANT. QUAL. QUANT. 
- . PROC. 1 2 PRE PROC. 1 2 PRE 
CODE POS. NEG. FIX RESULT CODE POS. NEG. FIX RESULT 
01 llSl-AOl c:J D 0 0 L 1111 CJ D 0 0 I I I I I I 
(19-20) (211 (221 (23-271 (28-291 (30) (31) (32·36) 
01 RS1-A02 c:J D 0 D L J I I I CJ 0 0 0 I I I I I I 
(41·42) (43) (44) (45·49) . (50.51) (52) (53) (S4-58) . 
01 llS1-A03 CJ 0 0 D I I I I l D 0 0 D I I I I I I 
(63-64) (65) (661 (67·71) (72·73) (74) (75) (76-80) 
01 ltS1-A04 CJ 0 0 0 I I I I I CJ 0 D 0 I I I I I I 
(19-201 (211 (221 (23-27) (28·29) (30) (31) (32·36) 
01 ltSl-A05 t::J 0 0 0 lJJJ I CJ 0 0 0 I I I I I I 
(41-42) (43) ~41 (4S·49) (50.511 (521 (53) (54-58) 
/" 
01 llSl-A06 D D -0 0 L 1 I I I CJ D D 0 I I I I I I 
(63-64) (65) (66) (67·711 (72·73) (74) (75) (76-80) 
01 ltSl-A07 CJ D 0 0 L 11 I I CJ 0 0 0 I I I I I I 
(19-201 (211 (22) (23-27) (28·291 (30) (31) (32·36) 
01 ltSl-A08 CJ 0 0 0 ll1 I I CJ 0 
I 
0 0 I I I I I I 
(41-42) (431 (441 (45-49) (50.51) (52) (53) (54-58) 
01 RS1-A09 D 0 0 0 I I I I I D D 0 0 I I I I I I 
(63-64) (65) (66) (67·71) (72·73) (74) (75) (76-80) 
01 BS1-A10 CJ D D D L 111 l CJ 0 D 0 I I I I I I 
(19·20) 1211 (22) (23·271 (28·29) (30) (311 (32·36) 
CDC 33.7 pg. 9 (formerly 3PT. B1J 
Rev. 3/81 
DEPARTMENT OF HEALTH AND HUMAN SERVICES 
PUBLIC HEALTH SERVICE 
CENTI:RS FOR OISr.ASE CONTROL 
Laboratory Improvement Propram Olflc:e 
Licensure •nd Proficiency Test1n9 Division 
Atlanta, Georvla 30333 
PROFICIENCY TESTING: RUBELLA SEROLOGY 
•· SPECIAL STUDY 
TEST HETllODOLOGY 
ro~·-·1 
LABORATORY CODE NUMBER 
Test Performed By: !Please Pnntl 
HEMAGGLUTINATION INHIBITION. (HAll 
SERUM TREATMENT (Circle one) 
1, Heparin • MnCI2 2. Dextran sulfate 3, Kaolin 
DILUTION TECHNIQUE (Circle onel 
1, Micro 2. Macro 
ANTIGEN MANUFACTURER: CEnter manufacturer code number and name) [[] ________________________ _ 
TYPE OF ERYTHROCYTES (Circle one) 
. 
9·12 13-14 15 
8107 33 2 





1, Chick 2. Duracytes (Abbott! 3. Human trypsinized 4, Pigeon 5. Goose 6. Other: specifY---------- (24) 
ANTIGEN TITRATION PERFORMED (Circle one) 
1. Single titration 2. In duplicate 3, In triplicate 4. More than triplicate: specify #-------- 5. Not titered in lab 
FREQUENCY OF ANTIGEN TITRATION (Circle one) 
1. Per vial of antigen 2. Per lot of antigen 3, Every run 4, Other: specify·----------
INACTIVATION OF SERUM time-temperature ___ (Circle one) 
1. Before treatment for non-specific inhibitors 2. After treatment for non·specific inhibitors 3. None 
RED BLOOD CELL ABSORPTION (Circle one) 
1. Yes 2. No 
CONTROL SERA USED (Circle one) 
1. High titered positive 2. High titered positive 3. Low titered positive 4. Other: specifY----------
Low titered positive Negative Negative 
Negative 
BACK TITRATION PERFORMED: !Circle one) 
1. As single titration. 2. In duplica\e 3. In triplicate 4. More than triplicate: specify No.----------
FREQUENCY OF BACK TITRATION !Circle one) 
1. Per vial of antigen 2. Per lot of antigen 3. Every run 4. Other: specifv----------









PASSIVE HEMAGGLUTINATION TEST CPHA) Procedure 16 (6S.66i 
Kit or Reagent Manufacturer: CEnter manufacturer code number and name) [[] ______________________________ _ 
Controls UMd: (Circle no more than three): 
.1. Pos. high titer 3. Negative 
2. Pos. low titer 4. Other: specify ----------
TEST USED FOR (Circle onel 
1. Screening only 2. Titer determination 
Significam Tit•: ,_I_..._--J-..&..-J 
OTHER PROCEDURES: 
Enter procedure code number OJ 
Kit or Reagent Manufacturer: (Enter manufacturer code number and name) [J] _________________________________ _ 










Report Forms and Instructions Mailed to 
Laboratories Selected to Assay for Rheumatoid Factors 
., ....... .. '"· 
~·· . 41 DEPARTMENT OF IlEAL TH & HUMAN SERVICES 
b .. f{l_ 
Public Health Service 
•••• ~"7 ... ,;ICI,~ 
. -· 
Participants 
CDC Proficiency Testing Program 
General Immunology - Special Study 
PLEASE READ AND FOLLOi-1 THE INSTRUCTIONS CAREFULLY. 
Centers for Disease Control 
Atlanta, Georgia 30333 
March 31. 1982 
This General Immunology (Special Study) Shipment consists of 10 serum 
samples. The tests to be performed on these samples are indicated in 
the instructions. 
The samples have been tested and found to be negative for Hepatitis B 
surface antigen (HBsAg); however, negative test results do not assure 
the absence of the agent ~esponsible for causing hepatitis. Therefore, 
the samples should be handled with .the same precautions that are applied 
to processing your patient samples, namely, that etiologic agents should 
be presumed to be present. 
lf you have questions concerning this shipment, contact the Specimen 
Coordinator (Person-to-Person) at (404)329-3871. 
-
Report forms should be returned to CDC no later than April 14, 1982. 





The samples in this shipment are to be tested for Rheumatoid Factors {RF) 
using Latex Agglutination-slide and/or tube. 
Report results ·in International Units/ml {I.U./ml). 
I U I 1 (u k ) _ Titer of Unknown x 1000 I. U ./ml • • m n nown - f d d Titer o Stan ar 
REPORTING RESULTS 
1. Be sure to eater your correct laboratory code number in the space provided. 
2. Enter the number 12 for the Latex Agglutination tube test procedure code 
(PROC. CODE). Enter the number 13 for the latex agglutination slide test 
procedure code. 
3. Two columns are provided for results. If tests are performed in duplicate, 
report both values. If tests are not performed in duplicate, enter results 
in the left column. 
4. Enter results as whole numbers. For example enter 00320 NOT 1:320 or 1/320. 
Fill in leading zeros. · rQlfQliJ1'211Ql round decimals to the nearest 
whole number. LJ ~ L::l L=.1 ~ 
5. For Negative or Non-reactive results: 
Report either qualitative negative or Prefix 3 and the lowest detectable 
level. If you normally report quantitative resultsr report Prefix 3 {less 
than) and the lowest dilution tested. For "less than 20" ..: enter 11 3" in 
the box under PREFIX and 00020 in the boxes for quantitative result. 
DO NOT REPORT ALL ZEROS. 
6. For Indefinite Positive Results: 
If a result is "greater than" or "equal to or greater than" the highest 
level normally tested, enter the highest level tested in the quantitative 
result and in the PREFIX box, enter 111" for "greater than" or "2" for 
"equal to or greater than. 11 Leave the PREFIX box blank if an endpoint 
is obtained. 
MANUFACTURER - CODE LIST 




04 Antibodies Inc. 
05 Atlanti.c Antibodies 




14 Bio Diagnostics 
15 Bioquest - (BBL) 
16 Biaware 
17 Bio Dx 
21 Canalco 
22 Cappell 
23 Clinical Assays 
24 Cooke 
25 Cordis 
26 Clinical Sciences Inc. (CSI) 
31 Dade 
32 Difco 
35 Electro Nucleonics 







48 Hynson Wescott Dunning 
51 Industrial Biological Laboratories (IBL) 
52 ICL Scientific 
53 International Diagnostic Technology (IDT) 
56 Kallestad 
61 Laboratory Diagnostics 
Lederle - see Fisher 
63 Lee 
64 Linbro 
66 M.A. Bioproducts 
67 Ncloy 
68 Microbiological Research Corp. 
69 l-lill ipore 
Manufacturer Code No. 
71 New England Nuclear 
72 North American-Biologicals 


















97 Local Manufacture (prepared by 
using laboratoty) 
98 Noncommercial 

















CDC 33.7 pg, 9 (formerlY 3PT. 81) 
Rev. 3/81 
• DEPARTMENT OF HEALTH AND HUMAN SERVICES 
PUBLIC HEALTH SERVICE 
CENTERS FOR DISEASE CONTROL 
BUREAU OF LABORATORIES 
ATLANTA, GEORGIA 30333 




I I I 
(9-10) (11-12) 
I I 
LABORATORY I I I I I 81 33 I I l I I CODE NUMBER 
RESULT 
QUAL. QUANT. 
PROC. 1 2 PRE PROC. 
CODE POS. NEG. FIX RESULT CODE 
c::J D 0 D I I I I I CJ 
(19·20) (21) (22) (23-27) (28-29) 
CJ D 0 D I I I I I CJ 
(41·42) (43) (44) (45-49) . (50.51) 
CJ 0 D D L I I I I CJ 
(63-64) (65) (66) (67·71) (72~73) 
CJ D D D I I I I I CJ 
(19-20) (21) (22) (23-27) (28·29) 
CJ 0 D 0 L I I I I CJ 
(41-42) (43) &441 (45-49) (50.51) 
~/-
D D 0 0 L I I I I CJ 
(63-64) (65) (66) (67·71) (72·73) 
CJ D D 0 L I I I I CJ 
(19-20) (21) (22) (23-27) (28-29) 
CJ 0 0 D I I I I I CJ 
(41-42) (43) (44) (45·49) (50. 51) 
CJ D D 0 L I I I I D 
(63-64) (65) (66) (67·71) (72·73) 
CJ 0 D 0 L I I I I CJ 
(19·20) (21) (22) (23·27) (28·29) 
. 




1 2 PRE 
POS. NEG. FIX RESULT 
D 0 0 I I I I I I 
(30) (31) (32-36) 
D 0 0 I I I I I I 
(52) (53) (54-58) 
D 0 D I I I I I I 
(74) (75) (76-80) 
D 0 D I I I I I I 
(30) (31) (32·36) 
0 0 0 I I I I I I 
(52) (53) (54-58) 
D D 0 I I I I I I 
(74) (75) (76-80) 
0 0 0 I I I I I I 
(30) (31) (32-36) 
I 
D 0 D I I I I I I 
(52) (53) (54-58) 
D D 0 I I I I I I 
(74) (75) (76·80) 
D D D I I I I I I 
(30) (31) (32·36) 
DEPARTMENT OF HEALTH AND HUMAN SERVICES 
PUBLIC HEALTH SERVICE 
CENTERS FOR DISEASE CONTROL 
BUREAU OF LABORATORIES 
ATLANTA, GEORGIA 30333 




8 : ; r r 
I 9-12 13·14 15 I 
I I I I I 
I I I I I 8101 33 I I I I I 1 
LABORATORVCOOENUMDER I I I I I 
Test Perlormcd By. (Please Prontl 
SLIDE TEST: (Enter procedure code number) 
Kit Manufacturer: (Circle one) Lot • ----- Exp. Date -----
1. Behring 6. Hyland 11. Svtvane 16. Palomar 
2. BCAiSchering 
3. Difco 
12. Wampole Rheumaton 
13. Wampole R3 
7. ICL 
B. Laboratorv Diagnostics 
4. Gamma 9. Organon 14. Wellcome 
5. HWO 10. Organon (DRI Dod 15. Other: specify---------------
Ia MNm in.ctivated before testing: (Circle one) 
1. No 2. Yes - 56" 30 min 3. Yes _ •c ----.min 
Lowest dilution of 11rum tested: (Circle one) 
1. Undiluted 2. 1:10 3. 1:20 4. Other specify: -------------
Are additional dilutions tilted on llide: (Circle one) 
1. No 2. Yes - beginning with 1: _ through 1: ----
Endpoint reec:tion: Least reaction considered positive is: (Circle one) 
1. 1+ 2. 2+ 3. 3+ 4. 4+ 5. Trace 6. Anv 7. EQual to_positive control 
Controls used each run: (Circle maximum of thrHI 
1. Positive from kit 2. Negative from kit 3. None 4. Known strong positive 5. Known weak positive 6. Known n119ative 
Source of standard: See under Latex Tube Test. 
LATEX TUBE TEST: 
Re~pnt or Kit Manufacturer: (Enter manufacturer code number and name) Lot • ------ Exp. Date----OJ _____________________________ __ 
Is 11rum inactivated before testing (Circle one) 
1. No 2. Yes - 56"C 30 min 3. Yes--·C-min 
Test Procedure: (Circle one) 
1. EQual volumes of serum dilution and latex antigen suspension 
2. Constant volume of serum dilution and one drop of latex antigen suspension 
3. Other: specify-------------------------------------------
Initial incubation: (Circle one for each group) 
Time: 1. 15 min 2. 30 min 3. 60m1n 4. 90 min 5. 120 min 6. Overnight 7. Other: specify_ 
Temperature: 1. Room temp. 2. 3TC 3. 56"C 4. Other: specify---------
Is test subseQuently refrigerated overnight? 1. Yes 2. No 
Endpoint reaction: Laast reaction comidered positive is: (Circle one) 
1. 1+ 2. 2+ 3. 3+ 4. 4+ 5. Trace 6. Any 7. EQual to positive control 
Controls used each run: !Circle maximum of three) 
1. Positove from kit 2. Negatove from kit 3. None 4. Known strong posotlve 5. Known weak positive 6. Known negative 
R11ults reponed are based on: (Circle one) 
1. Initial serum dilUtiOns 2. Final serum dilutions 
What do you consider a significant tiler? 
Source of standard: nlL.-..1.......1----------------INama and Code No.} 
CDC 3P 1.2M Hev. 9/80 
1 
c:c 
(1 ~17) 
U8·19) 
(20.21) 
(22) 
(23) 
(24) 
(25) 
(2~28) 
(30.31) 
(32·33) 
(34) 
(35) 
(36) 
(37) 
(38) 
(39) 
(40.42) 
(43) 
(44·46) 
(47-48) 
I 
I 
I 
